Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 maintenance pemetrexed versus placebo after induction chemotherapy in advanced non-small cell lung cancer
2004-002425-52Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Jan 2005; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-002425-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002425-52.